ONDANSETRON - A NEW SAFE AND EFFECTIVE ANTIEMETIC IN PATIENTS RECEIVING HIGH-DOSE MELPHALAN

被引：25

作者：

VINER, CV

SELBY, PJ

ZULIAN, GB

GORE, ME

BUTCHER, ME

WOOTTON, CM

MCELWAIN, TJ

机构：

[1] ROYAL MARSDEN HOSP,SUTTON,SURREY,ENGLAND

[2] GLAXO GRP RES LTD,GREENFORD UB6 0HE,MIDDX,ENGLAND

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 1990年 / 25卷 / 06期

关键词：

D O I：

10.1007/BF00686058

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A total of 33 patients with myeloma receiving treatment with high-dose melphalan (140-200 mg/m2 i.v.) were given the 5HT3 antagonist Ondansetron (Glaxo) as an antiemetic. In 42% of patients, emetic episodes were either abolished (15%) or reduced to two or less (27%). Efficacy was not related to scheduling (two regimens) or total dose. No sedative or other significant side effects were seen. Ondansetron is a highly effective non-sedative antiemetic that justifies further assessment in combination with other antiemetics in patients receiving cytotoxic drugs associated with the production of severe nausea and vomiting. © 1990 Springer-Verlag.

引用

收藏

页码：449 / 453

页数：5

相关论文

共 15 条

[1] HIGH-DOSE MELPHALAN AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR SOLID TUMORS OF CHILDHOOD [J].

BAGNULO, S ;

PEREZ, DJ ;

BARRETT, A ;

MELLER, S ;

MCELWAIN, TJ .

EUROPEAN PAEDIATRIC HAEMATOLOGY AND ONCOLOGY, 1985, 2 (03) :129-133

[2] THE ANTI-EMETIC POTENTIAL OF THE 5-HYDROXYTRYPTAMINE3 RECEPTOR ANTAGONIST BRL-43694 [J].

BERMUDEZ, J ;

BOYLE, EA ;

MINER, WD ;

SANGER, GJ .

BRITISH JOURNAL OF CANCER, 1988, 58 (05) :644-650

[3]

BOWMAN A, 1988, 13TH C EUR SOC MED O

[4]

BRITTAIN R T, 1987, British Journal of Pharmacology, V90, p87P

[5] PHARMACOKINETICS AND ANTI-EMETIC EFFICACY OF BRL43694, A NEW SELECTIVE 5HT-3 ANTAGONIST [J].

CASSIDY, J ;

RAINA, V ;

LEWIS, C ;

ADAMS, L ;

SOUKOP, M ;

RAPEPORT, WG ;

ZUSSMAN, BD ;

RANKIN, EM ;

KAYE, SB .

BRITISH JOURNAL OF CANCER, 1988, 58 (05) :651-653

[6]

COSTALL B, 1987, BRIT J PHARMACOL, V90, P90

[7] PREVENTION OF EMESIS IN PATIENTS RECEIVING CYTOTOXIC DRUGS BY GR38032F, A SELECTIVE 5-HT3 RECEPTOR ANTAGONIST [J].

CUNNINGHAM, D ;

POPLE, A ;

FORD, HT ;

HAWTHORN, J ;

GAZET, JC ;

CHALLONER, T ;

COOMBES, RC .

LANCET, 1987, 1 (8548) :1461-1463

[8] THE EFFICACY OF GR38032F, AN ANTAGONIST OF 5-HYDROXYTRYPTAMINE-3 (5-HT3) IN THE PROPHYLAXIS OF CISPLATIN (CDDP)-INDUCED NAUSEA AND VOMITING [J].

DEHAAN, LD ;

DEMULDER, PHM ;

BEEX, LVAM ;

DEBRUYNE, FMJ ;

CHALLONER, T ;

DEPAUW, BE .

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (08) :1383-1384

[9]

HELENGLASS G, 1988, BONE MARROW TRANSPL, V3, P21

[10] DOSE-RANGING EVALUATION OF THE SEROTONIN ANTAGONIST GR-C507/75 (GR38032F) WHEN USED AS AN ANTIEMETIC IN PATIENTS RECEIVING ANTICANCER CHEMOTHERAPY [J].

KRIS, MG ;

GRALLA, RJ ;

CLARK, RA ;

TYSON, LB .

JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (04) :659-662